TorreyPines Therapeutics (Nasdaq:TPTX) is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies. Our goal is to develop versatile small molecule product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia, or dry mouth, and cognitive disorders. |
|
 |
06/30/2008 |
Data Presented at American Headache Society’s Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics’ Tez |
 |
06/23/2008 |
Register for Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate |
|
06/23/2008 |
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society |
|
06/20/2008 |
Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate |
|
06/04/2008 |
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel |
|
05/21/2008 |
Listen to Dr. Neil Kurtz Present at the JMP Seventh Annual Securities Conference |
|
